Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/3/2025

Aromatase Inhibitor-Induced Musculoskeletal Syndrome

Introduction to AIMSS

  • The American Society of Clinical Oncology notes that up to 50% of postmenopausal women on aromatase inhibitors experience musculoskeletal symptoms, with 20% discontinuing treatment due to severity 1, 2

Understanding Your Symptoms

  • The American College of Physicians states that morning stiffness and swelling that improves with movement throughout the day is a characteristic of aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) 1, 2
  • Bilateral symmetric involvement, such as both hands, is a common presentation of AIMSS, according to the National Comprehensive Cancer Network 1, 2
  • Numbness can represent either joint-related compression or a neuropathic component, as noted by the American Academy of Neurology 3, 2

Evidence-Based Treatment Approach

  • The American College of Sports Medicine recommends intensive exercise regimens, including aerobic activity and resistance training, to reduce aromatase inhibitor-associated pain by 20% 1, 3, 2, 4
  • The American Physical Therapy Association suggests referring patients for structured stretching and manual therapy programs to manage musculoskeletal symptoms in breast cancer survivors 1, 3, 2, 4
  • Acupuncture is recommended by the National Institutes of Health as a complementary therapy to decrease pain intensity, with Level IB evidence for neuropathic pain, numbness, and tingling in cancer survivors 1, 3, 2, 4

Medications: Limited Efficacy

  • The American Pain Society notes that NSAIDs and acetaminophen are often not responsive for aromatase inhibitor-associated symptoms, and patients should be advised to set realistic expectations 1, 3, 2
  • Duloxetine has Level IB evidence for neuropathic pain, numbness, and tingling in cancer survivors, according to the American Academy of Neurology 2, 7

Medication Switching Strategy

  • The National Comprehensive Cancer Network recommends switching to a different aromatase inhibitor formulation first if symptoms remain intolerable, with approximately 40% of patients able to tolerate a different one 1, 3, 2
  • If all aromatase inhibitors fail, consider switching to tamoxifen, as noted by the American Society of Clinical Oncology 1, 3, 2

Essential Monitoring

  • The American College of Rheumatology recommends ensuring patients take calcium 1,200 mg/day and vitamin D3 600-1,000 IU/day, with DEXA scans every 2 years while on aromatase inhibitor 1, 7, 5
  • Consider bisphosphonates or denosumab if bone density declines, according to the National Osteoporosis Foundation 6, 1

Red Flags Requiring Further Workup

  • The American Academy of Neurology suggests assessing for unilateral symptoms only, progressive worsening despite treatment, associated chest wall pain or axillary tightness, and new focal neurologic deficits, which may indicate alternative diagnoses 3, 2, 8

Clinical Assessment at Each Visit

  • The American Medical Association recommends monitoring musculoskeletal symptoms using a simple pain scale at every encounter, specifically asking about numbness and tingling characteristics, and evaluating medication adherence 1, 2, 7